Kanisa Pharmaceuticals Report issue

For profit Phase 2 Phase 3
Founded: San Diego CA United States (2004)
Status: Defunct (2015)

Organization Overview

First Clinical Trial
2004
NCT00046930
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2005

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Refractory (Phase 3)

Anemia, Refractory, with Excess of Blasts (Phase 3)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Myelodysplastic Syndromes (Phase 3)

Preleukemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5